Physician Response to Implementation of Genotype-Tailored Antiplatelet Therapy

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 1, 2016, Pages 67-74

  Peterson, J F ^a   Field, J R ^a   Unertl, K M ^a   Schildcrout, J S ^a   Johnson, D C ^a   Shi, Y ^a   Danciu, I ^a   Cleator, J H ^a   Pulley, J M ^a   McPherson, J A ^a   Denny, J C ^a   Laposata, M ^a   Roden, D M ^a   Johnson, K B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ADULT; ARTICLE; BARE METAL STENT; CARDIOLOGIST; CLINICAL DECISION MAKING; COMPUTERIZED PROVIDER ORDER ENTRY; CORONARY STENT; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; AGE; AGED; ANALOGS AND DERIVATIVES; CLINICAL PRACTICE; GENETIC VARIATION; GENETICS; METABOLISM; MIDDLE AGED; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; STENT;

AGE FACTORS; AGED; CLINICAL DECISION-MAKING; CYTOCHROME P-450 CYP2C19; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; PRECISION MEDICINE; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 84975780844     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.331     Document Type: Article

References (37)

1. Gu, Q., Dillon, C.F. & Burt, V.L. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief 1-8 (2010).
2. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300, 2867 (2008).
3. Pharmacogenomic Biomarkers in Drug Labels. FDA Pharmacogenomic Biomarkers in Drug Labeling. .
4. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458 (2012).
5. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
6. McCarty, C.A. et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4, 13 (2011).
7. Shuldiner, A.R. et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 94, 207-210 (2013).
8. Starren, J., Williams, M.S. & Bottinger, E.P. Crossing the omic chasm: a time for omic ancillary systems. JAMA 309, 1237-1238 (2013).
9. Peterson, J.F. et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet. Med. 15, 833-841 (2013).
10. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87-95 (2012).
11. Bell, G.C. et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. 21, e93-e00 (2013).
12. Mrazek, D.A. & Lerman, C. Facilitating clinical implementation of pharmacogenomics. JAMA 306, 304-305 (2011).
13. Daniel, J.L. et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024-2029 (1998).
14. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
15. Delaney, J.T. et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91, 257-263 (2012).
16. Holmes, M.V., Perel, P., Shah, T., Hingorani, A.D. & Casas, J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306, 2704-2714 (2011).
17. Johnson, J.A. et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin. Pharmacol. Ther. 91, 774-776 (2012).
18. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013).
19. Azmoon, S. & Angiolillo, D.J. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheter Cardiovasc. Interv. 81, 232-242 (2013).
20. Tantry, U.S. et al. Consensus and update on the definition of ontreatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261-2273 (2013).
21. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
22. Alexopoulos, D. et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19∗2 genotyping. JACC Cardiovasc. Interv. 4, 403-410 (2011).
23. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
24. Desai, N.R. et al. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circ. Cardiovasc. Qual. Outcomes 6, 694-699 (2013).
25. Weitzel, K.W. et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166, 56-67 (2014).
26. Lee, J.A. et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 16, 303-313 (2015).
27. Peterson, J.F. et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J. (2015); e-pub ahead of print. doi:10.1038/tpj.2015.57.
28. Unertl, K.M., Field, J.R., Price, L. & Peterson, J.F. Clinician perspectives on using pharmacogenomics in clinical practice. Personal. Med. 12, 339-347 (2015).
29. Denny, J.C. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235-242 (2012).
30. Van Driest, S.L. et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin. Pharmacol. Ther. 95, 423-431 (2014).
31. CPIC dosing guidelines for clopidogrel. .
32. My Drug Genome. .
33. Khan, N.A. & Peterson, J.F. A surveillance tool to support quality assurance and research in personalized medicine. AMIA Annu. Symp. Proc. 2011, 701-708 (2011).
34. Mega, J.L. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011).
35. Price, M. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-105 (2011).
36. Price, M.J. et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124, 1132-1137 (2011).
37. Xu, H. et al. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19-24 (2010).